Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.
about
Cardiac remodelling and RAS inhibitionHemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate.Electroacupuncture improves cerebral blood flow and attenuates moderate ischemic injury via Angiotensin II its receptors-mediated mechanism in rats.Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan.Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused ratsRole of H(2)O(2) in hypertension, renin-angiotensin system activation and renal medullary disfunction caused by angiotensin II.Primacy of angiotensin converting enzyme in angiotensin-(1-12) metabolism.Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats.Are we ready to use aliskiren in children?The role of renin inhibition in treating the hypertensive patient with diabetes: a summary of preclinical and clinical evidence.Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.Integrative bioinformatics analysis of proteins associated with the cardiorenal syndromeChanges of gene expressions in spontaneously hypertensive rat model after losartan treatment.Additivity of nebivolol/valsartan single-pill combinations versus other single-pill combinations for hypertension.Characteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case-control study.TAK-272 (imarikiren), a novel renin inhibitor, improves cardiac remodeling and mortality in a murine heart failure model
P2860
Q28076749-F3112261-D4E1-4CEE-859E-A137604471BDQ30415031-D544B379-2097-452C-A1C5-5CE189550FE0Q33554921-F73BD597-4E7C-4DEF-BCD9-D9A1240C006EQ34544159-0D992223-63F0-4FEB-A81B-0B3150D45640Q34609451-32DB5D6A-02E4-4924-A7FD-6EBF12CFB6F8Q36132755-62F8E681-0245-436F-8419-EF2FEE39C8C6Q36252796-3B4168C7-7B9A-4DF2-A839-3EEDE724BBEAQ37142740-EDECACCD-9799-44D5-9026-287A91405700Q37233102-76B83834-61A1-4739-90C6-724BA63A7944Q37820390-3965BA58-5A01-4465-828B-55DEB4278DE5Q37980260-63566A8A-88AC-47A9-9803-BFD565FE26DBQ38750210-3CBBBF1A-73EB-4979-AA02-9FD33A0A0D9AQ41217019-7DE363AB-1A91-4BA3-9B69-B0FB35E50C25Q42404116-233E1D94-8906-4091-8DF7-E09FCEDC3CF9Q48359964-3D8DF82A-EE9C-4A16-98B3-3100B4B8B433Q55396649-CC216D47-E4CE-445D-B370-EF11181D0E05Q58794179-49DDB8A1-7E20-46DA-ADF2-B9BD394CCC67
P2860
Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Addressing the theoretical and ...... nd benefits beyond BP control.
@ast
Addressing the theoretical and ...... nd benefits beyond BP control.
@en
type
label
Addressing the theoretical and ...... nd benefits beyond BP control.
@ast
Addressing the theoretical and ...... nd benefits beyond BP control.
@en
prefLabel
Addressing the theoretical and ...... nd benefits beyond BP control.
@ast
Addressing the theoretical and ...... nd benefits beyond BP control.
@en
P2860
P1433
P1476
Addressing the theoretical and ...... nd benefits beyond BP control.
@en
P2093
Carlos M Ferrario
P2860
P304
P356
10.1016/J.LFS.2009.11.020
P407
P577
2009-12-01T00:00:00Z